Physicians should exercise caution when considering the use of filgrastim in patients with sickle cell disease and only after careful evaluation of the potential risks and benefits.
Filgrastiimi kasutamisel sirprakulise aneemiaga patsientide raviks peab arst olema ettevaatlik ning eelnevalt hindama raviga seotud võimalikke riske ja kasu.